Evidence map›Paper›PMID 30864086›Full record

ArticleInternational journal of clinical pharmacy2019

Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over.

Arim Kwak, Jae Hyun Kim, Cheol Ung Choi, In-Wha Kim, Jung Mi Oh, Kyungim Kim

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Arim KwakCollege of Pharmacy, Korea University, 251l Sejong-ro, Sejong, 30019, Republic of Korea.
Jae Hyun KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Seoul, 08826, Republic of Korea.
Cheol Ung ChoiCardiovascular Center, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea.
In-Wha KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Seoul, 08826, Republic of Korea.
Jung Mi OhCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Seoul, 08826, Republic of Korea.
Kyungim KimCollege of Pharmacy, Korea University, 251l Sejong-ro, Sejong, 30019, Republic of Korea. kim_ki@korea.ac.kr.ORCID http://orcid.org/0000-0001-7997-696X
Seoul National University · KRKorea University Medical Center · KRKorea University · KR

Funding

National Research Foundation of Korea NRF-2017R1C1B5018232
6 · The paper itself

Abstract

Background While there is clear evidence for the benefit of statins in the secondary prevention of cardiovascular and cerebrovascular events, there is a lack of research on the effects of statin regimens in older patients aged 75 years and over. Objectives To compare the effectiveness of statin regimens in the secondary prevention of ischemic cardiovascular and cerebrovascular events among patients aged 75 years and over. Setting Claims data from the South Korean National Health Insurance Database from 2006 to 2014. Methods This retrospective cohort study included patients aged 75-100 years with a prior history of cardiovascular or cerebrovascular disease who began statin therapy in 2009-2011. Propensity score matching and the Cox proportional hazards regression model were used to compare the effectiveness of the statin regimens in secondary prevention. Main outcome measure The hazard ratios for ischemic cardiovascular and cerebrovascular events and all-cause mortality. Results Neither high nor low-intensity statin therapy significantly differed from moderate-intensity statin therapy in preventing ischemic cardiovascular and cerebrovascular events or all-cause mortality. Of the moderate-intensity statin therapies, the use of 10 mg rosuvastatin was more strongly associated with a reduced risk of ischemic cardiovascular and cerebrovascular events than was 10 mg atorvastatin [HR 0.79 (95% CI 0.64-0.98), p = 0.029]. Subgroup analysis revealed that the protective effects of 10 mg rosuvastatin against ischemic cardiovascular and cerebrovascular events were more obvious for patients who were 75-79 years old, those who were statin-adherent, those who did not have diabetes mellitus at baseline, and those who were non-adherent to aspirin or antiplatelet drugs during the selection and follow-up periods. Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.

Indexed as

AgedAged, 80 and overAtorvastatinCardiovascular DiseasesCerebrovascular DisordersFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInsurance BenefitsInsurance, HealthMaleProtective FactorsRetrospective StudiesRosuvastatin CalciumSecondary PreventionAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumEffectivenessIschemic eventOlder peopleSecondary preventionSouth KoreaStatin

Identifiers

PMID30864086
OpenAlexW2922273615

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.